Selank is a synthetic heptapeptide developed in Russia, built as an analogue of the natural immune peptide tuftsin. It has been studied as an anxiolytic — in rat gene-expression experiments and in one small Russian human trial — and is described in the Western literature as poorly studied. It is not approved by the US FDA or the European Medicines Agency for any use. No reliable human half-life has been published.
By Tessaro Pty Ltd, the maker of Pepti · Last reviewed
This page is a reference, not a protocol. It sets out what the published research on Selank actually shows — and how small and how Russian that evidence base is — what can be said about its half-life, and what a clean log holds. It contains no dose figures and no schedule; a section below explains why that is deliberate, not an omission.
| Property | Value |
|---|---|
| Class / type | Synthetic heptapeptide; an analogue of the immune peptide tuftsin (Thr-Lys-Pro-Arg) extended with a Pro-Gly-Pro tail (Kolomin et al., 2013) |
| Origin | Developed in Russia; described in the Western literature as a Russian drug (Doyno and White, 2021) |
| Route in studies | Intranasal in the published studies (Kolomin et al., 2013; Zolotarev et al., 2006); parenteral in some studies |
| Evidence base | Small Russian studies — mostly rat mechanism work [animal], plus one small human trial in anxiety [human] (Volkova et al., 2016; Zozulia et al., 2008) |
| Half-life | No reliable human half-life has been published. |
| Regulatory status | Not approved by the US FDA or the European Medicines Agency (EMA); in the US sold only as a dietary supplement (Doyno and White, 2021) |
Selank is a synthetic heptapeptide developed in Russia, built as an analogue of tuftsin, a short natural immune peptide (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail; the literature refers to it directly as a tuftsin analogue (Kolomin et al., 2013). Its breakdown fragments begin with the tuftsin sequence, consistent with that structure (Zolotarev et al., 2006). It has been studied mainly as an anxiolytic.
The clearest human evidence is a single Russian trial. In 62 patients with generalized anxiety disorder and neurasthenia, Selank was compared with the benzodiazepine-type drug medazepam; the authors reported a similar anxiolytic effect for the two, with Selank also showing antiasthenic and mild stimulant effects (Zozulia et al., 2008) [human]. That is a small, single-country evidence base, and its English-language record is only an abstract — a signal, not proof.
The mechanistic work is preclinical and mostly in rats. Gene-expression studies in rat brain found that Selank alters genes involved in neurotransmission, and concluded that one plausible mechanism is allosteric modulation of the GABA system (Volkova et al., 2016) [animal]; a separate rat study of the hippocampus after intranasal Selank reported broad gene-expression changes (Kolomin et al., 2013) [animal]. These are animal findings, not demonstrations of benefit in people.
A clinical-pharmacology review is blunt: Selank is a poorly studied drug of Russian origin, with a GABA-related mechanism, sold to US consumers as a dietary supplement rather than an approved medicine (Doyno and White, 2021). It is not approved by the US FDA or the European Medicines Agency for any use.
No reliable human half-life has been published. Peptides of this kind are broken down quickly in the body: when tritium-labelled Selank was tracked, it was rapidly cleaved into smaller fragments (Zolotarev et al., 2006) [animal and laboratory] — consistent with a short-lived parent peptide, but not a human pharmacokinetic half-life.
Because there is no trustworthy figure, Pepti does not supply one. If you have a half-life value from whoever directs your use, you can enter it into the half-life tool and the app will model decay from your number. Whatever the half-life, the log can always hold the exact clock time of each administration — on a short-lived compound, precise timing is the most informative line in the record.
In the published studies, Selank is given intranasally (Kolomin et al., 2013; Zolotarev et al., 2006). Material prepared for injection is instead supplied as a powder that stays inert until a diluent is added; the two are different products, and a record that does not say which one it describes is ambiguous later. For a reconstituted vial, the concentration you create is the number every later draw depends on, so Pepti stores that concentration and the diluent volume as variables you enter.
Tracking Selank in Pepti is deliberately mechanical. If your vial is a powder, the reconstitution calculator turns the figures you already have — vial contents, diluent volume, the dose you were given — into a draw volume and a count of doses per vial, each held as a variable rather than a recommended amount. The injection-site rotation tracker keeps a 12-site sequence so the next administration lands somewhere other than the last. And because no trustworthy human half-life exists for this compound, the half-life calculator works only from a value you enter yourself.
Selank is not an approved medicine. There is no label from the FDA or the European Medicines Agency, so there is no authorised dose, no approved schedule, and no clinician-facing guidance outside the protocols of individual studies. In the United States it is sold as a dietary supplement, not an approved drug (Doyno and White, 2021), and a supplement label is not a dosing authority. Any figure published as a “typical dose” for an unapproved compound is not drawn from an approved source, because none exists — it comes from forum consensus, vendor copy, or someone’s reading of a study protocol run under monitoring conditions that do not apply elsewhere.
Pepti is a measurement and record-keeping tool. It converts a figure you already have into a draw volume and syringe units, tracks what is left in each vial, and remembers where the last administration went. It does not supply the figure, and it will not, for this compound or any other. Dose tables for unapproved peptides are folklore with the typography of evidence — authoritative-looking because they sit in a table, not because anything stands behind them. The figure belongs to you and whoever directs your use; the arithmetic is what we are for.
Because the effects people look for are largely subjective, the dated history is the part of a Selank log that earns its keep. A record worth keeping holds the following.
The method in full lives in the app: a peptide tracker keeps the dated log, the site sequence and your own entered half-life on one timeline, and the reconstitution calculator turns those figures into a draw volume and a count of doses per vial.
Selank is a synthetic heptapeptide developed in Russia. It was designed as an analogue of tuftsin, a short natural immune peptide (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail, and the literature refers to it as a tuftsin analogue (Kolomin et al., 2013). It has been studied mainly as an anxiolytic.
No. Selank is not approved by the US Food and Drug Administration or the European Medicines Agency for any use. A clinical-pharmacology review describes it as a poorly studied Russian drug that is sold to US consumers as a dietary supplement rather than as an approved medicine (Doyno and White, 2021).
No reliable human half-life has been published. Labelled Selank is cleaved quickly into smaller fragments in animal and laboratory studies, which points to a short-lived parent peptide but is not a human pharmacokinetic figure (Zolotarev et al., 2006). If you have been given a half-life value, you can enter it yourself and Pepti will use that number.
Mostly not. The mechanistic work is preclinical and largely in rats (Volkova et al., 2016; Kolomin et al., 2013). The main human evidence is a single Russian trial in 62 patients with generalized anxiety disorder and neurasthenia, in which Selank performed similarly to the comparator drug medazepam (Zozulia et al., 2008). That is a small, single-country evidence base, not a large randomized program.
No. Pepti supplies no dose figures for Selank or for anything else. It records the figure you already have from whoever directs your use, converts it into a draw volume and syringe units, tracks what is left in each vial, and keeps the site sequence. The arithmetic is ours; the figure is not.
This page is a reference on published evidence and record-keeping. It does not recommend Selank or any other substance, and it provides no dose figure, no titration amount, and no schedule. Selank is not approved for any use by the FDA or the European Medicines Agency.
The Pepti peptide tracker for iPhone keeps the dated log, the site sequence, the vial count and your own entered half-life in one place.
Not medical advice. Pepti is a record-keeping and measurement tool, not a medical device.
Get Pepti on the App Store